Prediction of optimal versus suboptimal cytoreduction of advanced-stage serous ovarian cancer with the use of microarrays

American Journal of Obstetrics and Gynecology

Volumn 190, Issue 4, 2004, Pages 910-923

  Berchuck, Andrew ^a,b   Iversen, Edwin S ^b   Lancaster, Johnathan M ^a   Dressman, Holly K ^b   West, Mike ^b   Nevins, Joseph R ^b   Marks, Jeffrey R ^b  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Debulking; Microarray; Ovarian cancer; Surgery

Indexed keywords

RNA;

ADULT; AGED; CANCER STAGING; CANCER SURGERY; CONFERENCE PAPER; CONTROLLED STUDY; DNA MICROARRAY; FEMALE; GENE EXPRESSION; GENETIC SCREENING; HUMAN; HUMAN TISSUE; NUCLEOTIDE SEQUENCE; OVARY CANCER; PRIORITY JOURNAL; PROGNOSIS; SEROSA; STATISTICAL MODEL; VALIDATION PROCESS;

EID: 2342442115     PISSN: 00029378     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ajog.2004.02.005     Document Type: Conference Paper

References (44)

1. W.P. McGuire W.J. Hoskins M.F. Brady P.R. Kucera E.E. Partridge K.Y. Look Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer N Engl J Med 334 1996 1 6
2. W.J. Hoskins W.P. McGuire M.F. Brady H.D. Homesley W.T. Creasman M. Berman The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma Am J Obstet Gynecol 170 1994 974 979
3. G.A. Omura M.F. Brady H.D. Homesley E. Yordan F.J. Major H.J. Buchsbaum Long-term follow-up and prognostic factor analysis in advanced ovarian carcinoma: the Gynecologic Oncology Group experience J Clin Oncol 9 1991 1138 1150
4. M. Markman B.N. Bundy D.S. Alberts J.M. Fowler D.L. Clark-Pearson L.F. Carson Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group J Clin Oncol 19 2001 1001 1007
5. J. Boyd T.C. Hamilton A. Berchuck Oncogenes and tumor suppressor genes W.J. Hoskins C.A. Perez R.C. Young Principles and practice of gynecologic oncology 2000 Lippincott, Williams and Wilkins Philadelphia 103 128
6. I. Hedenfalk D. Duggan Y. Chen M. Radmacher M. Bittner R. Simon Gene-expression profiles in hereditary breast cancer N Engl J Med 344 2001 539 548
7. M. West M. Blanchette H. Dressman E. Huang S. Ishida R. Sprang Predicting the clinical status of human breast cancer by using gene expression profiles Proc Natl Acad Sci USA 98 2001 11462 11467
8. M.J. van de Vijver Y.D. He L.J. van't Veer H. Dai A.A. Hart D.W. Voskuil A gene-expression signature as a predictor of survival in breast cancer N Engl J Med 347 2002 1999 2009
9. S.M. Dhanasekaran T.R. Barrette D. Ghosh R. Shah S. Varambally K. Kurachi Delineation of prognostic biomarkers in prostate cancer Nature 412 2001 822 826
10. R.E. Kass A.E. Raftery Bayes factor and model uncertainty J Am Stat Assoc 90 1995 773 795
11. I. Tannock Cell kinetics and chemotherapy: a critical review Cancer Treat Rep 62 1978 1117 1133
12. J.H. Golde A.J. Coldman A mathematical model for relating the drug sensitivity of tumors to the spontaneous mutation rate Cancer Treat Rep 63 1979 1727 1733
13. L. Zhang J.R. Conejo-Garcia D. Katsaros P.A. Gimotty M. Massobrio G. Regnani Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer N Engl J Med 348 2003 203 213
14. A. Berchuck M.F. Kohler J.R. Marks R. Wiseman J. Boyd R.C. Bast Jr. The p53 tumor suppressor gene frequently is altered in gynecologic cancers Am J Obstet Gynecol 170 1994 246 252
15. M.F. Kohler J.R. Marks R.W. Wiseman I.J. Jacobs A.M. Davidoff D.L. Clarke-Pearson Spectrum of mutation and frequency of allelic deletion of the p53 gene in ovarian cancer J Natl Cancer Inst 85 1993 1513 1519
16. L. Havrilesky K.M. Darcy H. Hamdan R.L. Priore J. Leon J. Bell A. Berchuck Prognostic significance of p53 mutation and p53 overexpression in advanced epithelial ovarian cancer. A gynecologic oncology group study J Clin oncol 21 2003 3814 3825
17. G. Casey M.E. Lopez J.C. Ramos S.J. Plummer M.J. Arboleda M. Shaughnessy DNA sequence analysis of exons 2 through 11 and immunohistochemical staining are required to detect all known p53 alterations in human malignancies Oncogene 13 1996 1971 1981
18. J.B. Welsh P.P. Zarrinkar L.M. Sapinoso S.G. Kern C.A. Behling B.J. Monk Analysis of gene expression profiles in normal and neoplastic ovarian tissue samples identifies candidate molecular markers of epithelial ovarian cancer Proc Natl Acad Sci U S A 98 2001 1176 1181
19. K. Ono T. Tanaka T. Tsunoda O. Kitahara C. Kihara A. Okamoto Identification by cDNA microarray of genes involved in ovarian carcinogenesis Cancer Res 60 2000 5007 5011
20. M. Schummer W.V. Ng R.E. Bumgarner P.S. Nelson B. Schummer D.W. Bednarski Comparative hybridization of an array of 21,500 ovarian cDNAs for the discovery of genes overexpressed in ovarian carcinomas Gene 238 1999 375 385
21. D.R. Schwartz S.L. Kardia K.A. Shedden R. Kuick G. Michailidis J.M. Taylor Gene expression in ovarian cancer reflects both morphology and biological behavior, distinguishing clear cell from other poor- prognosis ovarian carcinomas Cancer Res 62 2002 4722 4729
22. V. Shridhar J. Lee A. Pandita S. Iturria R. Avula J. Staub Genetic analysis of early- versus late-stage ovarian tumors Cancer Res 61 2001 5895 5904
23. G. Nawa Y. Miyoshi H. Yoshikawa T. Ochi Y. Nakamura Frequent loss of expression or aberrant alternative splicing of P2XM, a p53-inducible gene, in soft-tissue tumours Br J Cancer 80 1999 1185 1189
24. A.L. Sabichi D.T. Hendricks M.A. Bober M.J. Birrer Retinoic acid receptor beta expression and growth inhibition of gynecologic cancer cells by the synthetic retinoid N-(4-hydroxyphenyl) retinamide J Natl Cancer Inst 90 1998 597 605
25. G. De Palo L. Mariani T. Camerini E. Marubini F. Formelli B. Pasini Effect of fenretinide on ovarian carcinoma occurrence Gynecol Oncol 86 2002 24 27
26. R. Pergolizzi V. Appierto M. Crosti E. Cavadini L. Cleris A. Guffanti Role of retinoic acid receptor overexpression in sensitivity to fenretinide and tumorigenicity of human ovarian carcinoma cells Int J Cancer 81 1999 829 834
27. M. Chesi E. Nardini L.A. Brents E. Schrock T. Ried W.M. Kuehl Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3 Nat Genet 16 1997 260 264
28. C. Popovici B. Zhang M.J. Gregoire P. Jonveaux M. Lafage-Pochitaloff D. Birnbaum The t(6;8)(q27;p11) translocation in a stem cell myeloproliferative disorder fuses a novel gene, FOP, to fibroblast growth factor receptor 1 Blood 93 1999 1381 1389
29. S.D. Yamada J.A. Hickson Y. Hrobowski D.J. Vander Griend D. Benson A. Montag Mitogen-activated protein kinase kinase 4 (MKK4) acts as a metastasis suppressor gene in human ovarian carcinoma Cancer Res 62 2002 6717 6723
30. S. LoCoco A. Covens M. Carney E. Franssen R. Dogde B. Rosen Does aggressive therapy improve survival in suboptimal stage IIIc/IV ovarian cancer? A Canadian-American comparative study Gynecol Oncol 59 1995 194 199
31. G. Delgado D.H. Oram E.S. Petrilli Stage III epithelial ovarian cancer: the role of maximal surgical reduction Gynecol Oncol 18 1984 293 298
32. N.F. Hacker J.S. Berek L.D. Lagasse R.K. Nieberg R.M. Elashoff Primary cytoreductive surgery for epithelial ovarian cancer Obstet Gynecol 61 1983 413 420
33. J.D. Hainsworth W.W. Grosh L.S. Burnett H.W. Jones III S.N. Wolff F.A. Greco Advanced ovarian cancer: long-term results of treatment with intensive cisplatin-based chemotherapy of brief duration Ann Int Med 108 1988 165 170
34. R. Pohl G. Dallenbach-Hellweg T. Plugge B. Czernobilsky Prognostic parameters in patients with advanced ovarian malignant tumors Eur J Gynaecol Oncol 5 1984 160 169
35. J.R. Redman G.R. Petroni P.E. Saigo N.L. Geller T.B. Hakes Prognostic factors in advanced ovarian carcinoma J Clin Oncol 4 1986 515 523
36. G.P. Sutton F.B. Stehman L.H. Einhorn L.M. Roth J.A. Blessing C.E. Ehrlich Ten-year follow-up of patients receiving cisplatin, doxorubicin, and cyclophosphamide chemotherapy for advanced epithelial ovarian carcinoma J Clin Oncol 7 1989 223 229
37. S.E. Vogl M. Pagano B.H. Kaplan E. Greenwald J. Arseneau B. Bennett Cisplatin based combination chemotherapy for advanced ovarian cancer: high overall response rate with curative potential only in women with small tumor burdens Cancer 51 1983 2024 2030
38. M.S. Piver S.B. Lele D.L. Marchetti T.R. Baker L.J. Emrich A.B. Hartman Surgically documented response to intraperitoneal cisplatin, cytarabine, and bleomycin after intravenous cisplatin-based chemotherapy in advanced ovarian adenocarcinoma J Clin Oncol 6 1988 1679 1684
39. F. Guidozzi J.H. Ball Extensive primary cytoreductive surgery for advanced epithelial ovarian cancer Gynecol Oncol 53 1994 326 330
40. J.T. Soper G. Couchman A. Berchuck D. Clarke-Pearson The role of partial sigmoid colectomy for debulking epithelial ovarian carcinoma Gynecol Oncol 41 1991 239 244
41. S.M. Eisenkop R.L. Friedman H.J. Wang Complete cytoreductive surgery is feasible and maximizes survival in patients with advanced epithelial ovarian cancer: a prospective study Gynecol Oncol 69 1998 103 108
42. S.M. Eisenkop N.M. Spirtos Procedures required to accomplish complete cytoreduction of ovarian cancer: is there a correlation with “biological aggressiveness” and survival? Gynecol Oncol 82 2001 435 441
43. L.M. Chen R.S. Leuchter L.D. Lagasse B.Y. Karlan Splenectomy and surgical cytoreduction for ovarian cancer Gynecol Oncol 77 2000 362 368
44. J.L. Nicklin L.J. Copeland R.V. O'Toole G.S. Lewandowski L. Vaccarello L.P. Havenar Splenectomy as part of cytoreductive surgery for ovarian carcinoma Gynecol Oncol 58 1995 244 247